Trial · NCT04633447
Participant flow16
How many started, completed or left each group, period by period.
1 to 16 of 16
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Main Study (From Week 0 up to Week 60) | STARTED | Guselkumab | 35 | |
| Main Study (From Week 0 up to Week 60) | STARTED | Placebo | 18 | |
| Main Study (From Week 0 up to Week 60) | Participants Enrolled Post PA-5 Who Received Placebo Matching to Guselkumab 200 mg From Week 0 | Guselkumab | 0 | |
| Main Study (From Week 0 up to Week 60) | Participants Enrolled Post PA-5 Who Received Placebo Matching to Guselkumab 200 mg From Week 0 | Placebo | 11 | |
| Main Study (From Week 0 up to Week 60) | Participants Enrolled Post PA-5 Who Received Guselkumab 200 mg From Week 0 | Guselkumab | 19 | |
| Main Study (From Week 0 up to Week 60) | Participants Enrolled Post PA-5 Who Received Guselkumab 200 mg From Week 0 | Placebo | 0 | |
| Main Study (From Week 0 up to Week 60) | COMPLETED | Guselkumab | 22 | |
| Main Study (From Week 0 up to Week 60) | COMPLETED | Placebo | 12 | |
| Main Study (From Week 0 up to Week 60) | NOT COMPLETED | Guselkumab | 13 | |
| Main Study (From Week 0 up to Week 60) | NOT COMPLETED | Placebo | 6 | |
| LTE Period (Week 52 up to Week 112) | STARTED | Guselkumab | 9 | |
| LTE Period (Week 52 up to Week 112) | STARTED | Placebo | 6 | |
| LTE Period (Week 52 up to Week 112) | COMPLETED | Guselkumab | 5 | |
| LTE Period (Week 52 up to Week 112) | COMPLETED | Placebo | 3 | |
| LTE Period (Week 52 up to Week 112) | NOT COMPLETED | Guselkumab | 4 | |
| LTE Period (Week 52 up to Week 112) | NOT COMPLETED | Placebo | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04633447/flow